(Q31011194)

28 June 2017

1 reference

title

Prostate cancer progression after therapy of primary curative intent: a review of data from prostate-specific antigen era. (English)

1 reference

28 June 2017

1 reference

2

Mack Roach

1 reference

28 June 2017

1

Mark Soloway

1 reference

28 June 2017

language of work or name

English

0 references

publication date

1 December 2005

1 reference

28 June 2017

1 reference

28 June 2017

volume

104

1 reference

28 June 2017

issue

11

1 reference

28 June 2017

page(s)

2310-2322

1 reference

Inflammatory breast carcinoma: the sphinx of breast cancer research.

28 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the U.S. The American College of Surgeons Commission on Cancer and the American Cancer Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

Using PSA, biopsy Gleason score, clinical stage, and the percentage of positive biopsies to identify optimal candidates for prostate-only radiation therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

Dose selection for prostate cancer patients based on dose comparison and dose response studies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

Cancer fear and mood disturbance after radical prostatectomy: consequences of biochemical evidence of recurrence

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

Complications of advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

Caution in interpreting biochemical control rates after treatment of prostate cancer: length of follow-up influences results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen--driven outcome analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

The ability of the American Joint Committee on Cancer Staging system to predict progression-free survival after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

Analysis of clinicopathologic factors predicting outcome after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

The prognostic importance of Gleason grade in prostatic adenocarcinoma: a long-term follow-up study of 648 patients treated with radiation therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

A standard definition of disease freedom is needed for prostate cancer: undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

Retrospective stratification of a consecutive cohort of prostate cancer patients treated with a combined regimen of external-beam radiotherapy and brachytherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED PROSTATE CANCER

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

The 1989 patterns of care study for prostate cancer: five-year outcomes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

Serum prostate-specific antigen and survival after external beam radiotherapy for carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21441

7 January 2021

Identifiers

DOI

10.1002/CNCR.21441

1 reference

28 June 2017

1 reference